Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2024-04-23 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 Annual Report Summary" of 南京药石科技股份有限公司, which indicates it is a summary of the full annual report. It contains detailed financial data for the year 2023, including main accounting data, financial indicators, business overview, shareholder information, and bond information. The document references the full annual report and audit opinion, and includes comprehensive financial figures and business descriptions typical of an annual report. The length of the document (6854 characters) and the detailed financial content confirm it is not merely an announcement or a brief summary but a substantive report. Therefore, the document fits the definition of an Annual Report (10-K).
2024-04-23 Chinese
关于2024年度开展外汇衍生品交易业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 南京药石科技股份有限公司 regarding the company's plan to conduct foreign exchange derivative trading business in 2024. It details the purpose, investment amount, types of derivative products, risk analysis, risk control measures, accounting principles, and approval procedures. The document mentions that the proposal has been approved by the board and supervisory committee but still requires shareholder approval. It is a formal disclosure of a planned financing or capital risk management activity involving derivatives, not a financial report or earnings release. The document length is 3310 characters, which is relatively short and reads like an official announcement rather than a detailed report. There is no financial statement or detailed financial data presented. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing risk management and derivative trading activities for hedging purposes.
2024-04-23 Chinese
关于2023年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 annual profit distribution plan of the company, including details on cash dividends per share and the legal compliance of the plan. It includes resolutions from the board of directors and supervisory board approving the plan and states that the plan will be submitted to the shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2024-04-23 Chinese
2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2023 年度财务决算报告' which translates to '2023 Annual Financial Settlement Report'. It contains detailed financial data for the full year 2023, including income statement, balance sheet, cash flow statement, and detailed explanations of changes in financial items. The document mentions audited financial statements with an unqualified audit opinion. The length is 8494 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. The content corresponds to a full annual financial report rather than a short earnings release or a regulatory announcement. Therefore, the document fits the definition of an Annual Report (10-K).
2024-04-23 Chinese
2023募集资金年度存放与使用鉴证报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度募集资金存放与实际使用情况专项报告的鉴证报告" which translates to "2023 Annual Special Report on the Custody and Actual Use of Raised Funds with an Assurance Report." It includes detailed information about the company's fundraising activities, the amounts raised, the use of those funds, and the management of the funds. The document also contains an auditor's assurance report verifying the accuracy and compliance of the fundraising usage report with regulatory requirements. The presence of detailed financial data on fundraising, usage, and management, along with auditor verification, indicates this is a specialized report related to capital raising and fund usage rather than a general annual report or earnings release. This type of document fits best under the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising and capital usage activities. The document length is substantial (over 13,000 characters), and it contains substantive financial data and auditor's assurance, so it is not merely an announcement or certification. Therefore, the classification is CAP with high confidence.
2024-04-23 Chinese
药石科技2023环境、社会及公司治理（ESG）报告
Regulatory Filings
2024-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.